

**RESULTS OF INVESTIGATION:** Analysis showed that the article failed to meet the test specified in the National Formulary regarding permissible variations in the weight of individual containers. Analysis showed also that the individual containers contained from 42 percent to 117 percent of the declared amount of amobarbital.

**LIBELED:** 8-5-55, E. Dist. Va.

**CHARGE:** 501 (b)—the article, when shipped, purported to be and was represented as "Sodium Amobarbital," a drug the name of which is recognized in the National Formulary, an official compendium, and its strength differed from the standard set forth in such compendium; and 502 (a)—the label statement "Amobarbital Sodium 7½ gr." was false and misleading.

**DISPOSITION:** 12-6-55. Default—destruction.

**4935. Code #55 capsules.** (F. D. C. No. 38097. S. No. 19-715 M.)

**QUANTITY:** 2 cartons, 7,850 capsules each, at Columbus, Ohio.

**SHIPPED:** 1-11-52 and 11-13-52, from Detroit, Mich.

**RESULTS OF INVESTIGATION:** Analysis showed that the article contained less than the declared amount of vitamin C (ascorbic acid).

**LIBELED:** 7-20-55, S. Dist. Ohio.

**CHARGE:** 501 (c)—the strength of the article, while held for sale, differed from that which it purported and was represented to possess, namely, 50 milligrams of vitamin C per capsule; and 502 (a)—the label statement "Ingredients in each capsule: \* \* \* Ascorbic Acid U. S. P. 50 Mg." was false and misleading.

**DISPOSITION:** 8-25-55. Default—destruction.

**4936. Moe Pap liquid.** (F. D. C. No. 38101-A. S. No. 13-976 M.)

**QUANTITY:** 100 4-oz. btls. at Memphis, Tenn.

**SHIPPED:** 4-15-55 and 4-26-55, from St. Louis, Mo.

**RESULTS OF INVESTIGATION:** Analysis showed that the article contained less than 75 percent of the declared amount of vitamin B<sub>1</sub>.

**LIBELED:** 7-25-55, W. Dist. Tenn.

**CHARGE:** 501 (c)—the strength of the article, while held for sale, differed from that which it purported and was represented to possess, namely, 1,500 I. U. of vitamin B<sub>1</sub> per fluid ounce; and 502 (a)—the label statement "Thiamine Hydrochloride (Vitamin B<sub>1</sub>) 1500 I. U. per Fluid Ounce" was false and misleading.

**DISPOSITION:** 9-1-55. Default—destruction.

**4937. Ala-Dyne tablets.** (F. D. C. No. 38238. S. No. 29-309 M.)

**QUANTITY:** 1 1,000-tablet btl. and 608 100-tablet btls. at Emerson, N. J., in possession of Allied Drugs, Inc.

**SHIPPED:** 12-19-50 and 5-26-52, from Cleveland, Ohio.

**LABEL IN PART:** (Btl.) "Ala-Dyne Each Tablet Contains Acetylsalicylic Acid 4 grs. Calcium Glutamate 2 grs. Ascorbic Acid 30 mg. Allied Drugs, Inc. Hackensack, New Jersey Distributors Caution To be dispensed by or on the prescription of a physician. 2676 [or "4993"]."

**RESULTS OF INVESTIGATION:** The article was shipped in interstate commerce in bulk, and, upon receipt by the consignee, was repackaged. Analysis showed that lot number 2676 contained 76 percent of the labeled amount of acetylsalicylic acid.

**LIBELED:** 7-13-55, Dist. N. J.

**CHARGE:** (Btls. numbered 2676) 501 (c)—the strength of the article, while held for sale, differed from that which it purported and was represented to possess; (all btls.) 502 (a)—the label statement "Caution To be dispensed by or on the prescription of a physician" was false and misleading since the statement represented that the article was a prescription drug, whereas it was not such a drug but was safe and suitable for sale without a prescription, and its label should have contained adequate directions for use.

**DISPOSITION:** 9-13-55. Default—destruction.

**4938. Dormelix-B.** (F. D. C. No. 38482. S. No. 3-678 M.)

**QUANTITY:** 15 cartons, 12 1-pt. btls. each, at Boston, Mass.

**SHIPPED:** Sometime during 1950, from St. Louis, Mo.

**RESULTS OF INVESTIGATION:** Analysis showed that the article contained 53 percent of the declared amount of vitamin B<sub>1</sub>.

**LIBELED:** 10-5-55, Dist. Mass.

**CHARGE:** 501 (c)—the strength of the article, while held for sale, differed from that which it purported and was represented to possess; and 502 (a)—the label statement "Each Fluid Ounce Contains: \* \* \* Vitamin B<sub>1</sub> \* \* \* . . . . 3.0 mg. (1000 U. S. P. Units)" was false and misleading.

**DISPOSITION:** 12-5-55. Default—destruction.

**4939. Rauwolfia serpentina (powder and tablets).** (F. D. C. No. 37373. S. No. 13-086 M.)

**QUANTITY:** 1 65-lb. drum of the powdered drug, 420,000 uncoated and 35,000 coated 50-milligram tablets, and 100,000 uncoated and 70,000 coated 100-milligram tablets at Allentown, Pa.

**SHIPPED:** On 6-25-54, S. B. Penick & Co. shipped from Jersey City, N. J., a bulk lot of the drug in powder form.

**LABEL IN PART:** (Bulk drum) "Powdered Rauwolfia Serpentina Root."

**RESULTS OF INVESTIGATION:** The tablets were prepared by the consignee from a portion of the bulk powder in the above-mentioned shipment. Examination showed that the article in powdered form and in tablet form contained the ground root of a species of *Rauwolfia* other than *Rauwolfia serpentina*.

**LIBELED:** 12-1-54, E. Dist. Pa.

**CHARGE:** 501 (d) (2)—the article (in bulk and in tablet form), when shipped in the form of powder, was represented as *Rauwolfia serpentina*, and a substance other than *Rauwolfia serpentina* had been substituted in whole or in part; 502 (a)—the designation "Rauwolfia Serpentina" borne on the drum label of the article, when shipped, was false and misleading since such designation represented and suggested that the article in the bulk drum consisted wholly of *Rauwolfia serpentina*, whereas such was not the case; and 502 (i) (3)—the article (in bulk and in tablet form), when shipped, was offered for sale under the name of another drug.

**DISPOSITION:** 8-3-55. S. B. Penick & Co. having appeared and later having withdrawn as claimant, judgment of condemnation was entered and the product was ordered destroyed.

**4940. Rauwolfia serpentina.** (F. D. C. No. 37503. S. No. 3-085 M.)

**QUANTITY:** 252 lbs. in 3 cases at Stamford, Conn.